FRANKFURT, Jan 22 (Reuters) – The Bayer (BAYGn.DE) investor Union Funding criticized Bayer’s chair for an absence of engagement, resembling exploring a spin-off of the corporate’s shopper well being division, in line with an interview in WirtschaftsWoche.
Bayer is dealing with calls for from activist investor Bluebell Capital Companions to interrupt up, with a sale of the corporate’s shopper well being unit and, at a later stage, for a separation of Bayer’s prescription drugs and agriculture companies.
Bayer Chair Norbert Winkeljohann “does search dialogue with traders, however he ought to have initiated extra,” Markus Manns, portfolio supervisor at Union Funding, informed WirtschaftsWoche.
“It might positively have been a matter for the supervisory board to assist provoke a spin-off of Shopper Well being,” Manns added. He famous that chairs at opponents are far more engaged in creating worth for shareholders.
Winkeljohann didn’t instantly reply to a request for remark.
A spokesperson for Bayer declined to touch upon Union Funding’s place. “However typically talking we’re all the time open to a constructive dialogue with our stakeholders,” the spokesperson stated.
Reporting by Tom Sims
Enhancing by Tomasz Janowski
: .
